Brain Cancer Articles
-
Analytical Approaches and Applications of Whole Exome Sequencing (WES) in Oncology
Introduction Genomics has revolutionized cancer research, transforming the way we diagnose, treat, and monitor cancer. Among the powerful genetic analysis methods, Whole Exome Sequencing (WES) stands out as a cutting-edge technique that employs sequence capture technology to enrich DNA from the whole exome regions, enabling high-throughput sequencing. WES offers a simpler, more cost-effective, ...
By CD Genomics
-
It turns out that p53 is destroyed in a whole new way
Glioblastoma is a deadly brain cancer with a dire prognosis. Unlike most cancers, it still grows in the presence of the p53 protein. Scientists have been unable to solve the case for decades...until now. CSHL scientists have discovered that a protein called BRD8 goes out of control in glioblastoma, paralyzing P53. The discovery could help turn this deadly cancer into a treatable disease. Brain ...
-
The Future of Quantitative Susceptibility Mapping (QSM) in Clinical Applications
The use of Quantitative Susceptibility Mapping (QSM) is often viewed as incompatible with current standard radiology workflows. Some radiologists or departments may be unaware of its existence or purpose. Despite the skepticism surrounding its viability in a clinical setting, QSM shows great potential in a wide range of clinical applications, particularly for biomarker detection and ...
-
FDA Approved ALK Inhibitors for ALK-Positive Non-Small Cell Lung Cancer
Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a relatively rare and dangerous subtype, with patients suffering from a high incidence rate of brain metastases. Statistics show that about 55% of ALK-positive advanced NSCLC patients will develop brain metastases during ...
By BOC Sciences
-
What Are Hydrolytic Enzymes?
Alternatively referred to as hydrolases, the hydrolytic enzymes are used to split different groups of biomolecules, like esters, peptides, and glycosides. Moreover, hydrolytic enzymes can break down protein, lipids, nucleic acids, carbohydrates, and fat molecules to their simplest or smallest forms. Furthermore, lysosomal hydrolase comprises phosphatases, carboxylesterases, ribonuclease, ...
-
The Toxicity Atlas - One year later
It’s been about a year since I started my PhD project named The Toxicity Atlas. In this four-year project, I’m collaborating with researchers from Amsterdam UMC and my colleagues at Medstone to find better treatment options for patients with brain cancer. Let me tell you more about my results so far. Information databases Developing new drugs costs a lot of money and a lot of ...
-
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”. PROVIDENCE, R.I. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) ...
-
Dubai on the Brain: NeuroVigil’s Philip Low Assembles Dream Team to Launch Modern Neurotechnology Industry; Expands Conglomerate in Montreal, Canada
DUBAI, United Arab Emirates & PALO ALTO, Calif. & MONTREAL--(BUSINESS WIRE)--Neurotechnology Powerhouse NeuroVigil (ranked “Top 10 most innovative companies in health care” by Washington Post and Fast Company) announced at the New Technology & Mental Health Conference keynote during Dubai’s World Expo that it has recruited senior captains of industry, government and ...
-
ZAP Surgical Receives CE Mark Clearance for its ZAP-X Gyroscopic Radiosurgery Platform
ZAP Surgical Systems, Inc. today announced it has received CE mark clearance to the new EU MDR for its ZAP-X® Gyroscopic Radiosurgery® platform. The CE mark makes it possible for healthcare providers to begin treating patients with the ZAP-X system in the European Union. For select indications including many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) is proven ...
-
Intracranial Neoplasms: The Evolution of Radiotherapies
CURRENT STANDARD OF CARE FOR BRAIN TUMORS The current initial standard of care for aggressive brain tumors—whether they are primary brain tumors (ie, tumors that originate in the brain), or metastatic tumors from cancers that started outside of the brain—is resection. After surgery, a follow-up treatment, also referred to as adjuvant treatment, is often recommended to help eliminate ...
-
GammaTile Surgically Targeted Radiation Therapy (STaRT) Improving Access to Brain Tumor Care without Compromising Outcomes
ABSTRACT Patients with brain tumors face enormous challenges after diagnosis. Many of these challenges are amplified by issues related to access to care.1‒4 Studies suggest that patients with cancer who live farther from radiation treatment centers have poorer clinical outcomes. In addition, minorities are more likely to perceive longer travel distances as a barrier, which may cause them ...
-
ZAP Surgical’s Gyroscopic Radiosurgery Platform Receives Japanese Shonin Approval
ZAP Surgical Systems, Inc. today announced it has received Shonin approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for its ZAP-X® Gyroscopic Radiosurgery® platform. As part of the approval, ZAP-X is now cleared for clinical use in Japan. To facilitate a robust market introduction effort, ZAP also announced a partnership with MC Medical Inc. to lead Japanese ...
-
ZAP Surgical Announces First Facility on the East Coast Initiates Patient Treatment Using New Non-Invasive Brain Tumor Therapy
ZAP Surgical Systems, Inc. today announced ZAP-X® Gyroscopic Radiosurgery® patient treatments have commenced at MedStar Georgetown Cancer Institute at MedStar Southern Maryland Hospital Center in Clinton, MD. For many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) has proven to be an effective treatment with outcomes equivalent to invasive surgical procedures. ...
-
2019 Year in Review by President & CEO Matt Likens
As we embark on 2020, I find myself reflecting on the incredible growth GT Medical Technologies has experienced during the past year. We are filled with optimism knowing that each milestone along our journey represents new hope for patients with brain tumors. 2019 SCIENTIFIC AND BUSINESS ACHIEVEMENTS Completing our $10 Million Series A financing for commercialization Publishing the ...
-
ODS Medical joins forces with two American Giants
ODS Medical will undertake within a few weeks the first official clinical trial which will allow it to test its surgical probe, a tool capable of discerning, in real time, cancerous tissue from healthy tissue in brain operated patients. But before arriving there, she chose to surround herself well. The company has just signed an agreement with an American medical equipment manufacturer whose ...
-
ODS Medical is a 2018 Medtech Innovator Showcase Company
Summary: In treating brain cancers, neurosurgeons face a critical decision: remove too little tissue and risk fatal recurrences or remove too much and cause profound neurological damage. Presently, they rely on pre-operative surgical navigation technologies, such as MRI, in order to determine the contours of the cancerous tissue to be safely removed. These surgical navigation systems, in ...
-
Montreal-developed probe could be breakthrough in finding cancer (Montreal CTV News)
A fibre-optic probe can detect errant cancer cells within healthy tissue during brain tumour surgery with close to 100 per cent accuracy and sensitivity, reducing the risk of recurrence and thereby increasing a patient’s survival time, say the Canadian researchers who developed the device. The hand-held, pen-like instrument, known as a Raman spectroscopy probe, is able to differentiate ...
-
Presumption for selected cancers and occupation as a firefighter in Manitoba: the rationale for recent Canadian legislation on presumption
Provinces across Canada are suddenly considering or have already passed legislation establishing a rebuttable presumption for compensation for firefighters who develop certain types of cancer. This movement began in Manitoba and was motivated by appreciation of the role of firefighters in public safety. The evidentiary basis for establishing presumption for these cancers was developed in a report ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you